){kind=logo}
Loeb & Loeb represented China SXT Pharmaceuticals, Inc., an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, in its $9 million registered direct offering.
The offering consisted of 4,500,000 units, each comprised of one Class A ordinary share and one common warrant, sold at a purchase price of $2.00 per unit.
The aggregate gross proceeds from the offering were approximately $9 million. The transaction closed on July 24, 2026.
The Loeb team included Lawrence Venick, managing partner of the firm’s Hong Kong and Beijing offices, and Capital Markets associate Rongwei Xie.
For more information, please see the company’s press release.
The offering consisted of 4,500,000 units, each comprised of one Class A ordinary share and one common warrant, sold at a purchase price of $2.00 per unit.
The aggregate gross proceeds from the offering were approximately $9 million. The transaction closed on July 24, 2026.
The Loeb team included Lawrence Venick, managing partner of the firm’s Hong Kong and Beijing offices, and Capital Markets associate Rongwei Xie.
For more information, please see the company’s press release.
-
Managing Partner, Hong Kong and Beijing Offices -
Associate